The plant hormone abscisic acid (ABA) controls many important physiological processes, including seed germination, bud dormancy and adaptive responses to environmental stresses such as drought and salinity. Whereas downstream mediators of ABA signaling have been established, the protein receptors for ABA have eluded identification for many years because of the high level of receptor redundancy. Through chemical genetics and yeast two-hybrid screening, a new class of START proteins has recently been described as ABA receptors in Arabidopsis thaliana [1] [2] [3] . These receptors are designated as pyrabactin resistance 1 (PYR1) and 13 members of PYR1-like (PYL) receptors 1 or as regulatory components of ABA receptors (RCAR) 2 . ABA binding to these receptors increases their ability to bind and inhibit type 2C protein phosphatases (PP2Cs), such as ABI1, ABI2 and HAB1. In the absence of ABA, these PP2Cs bind and inactivate subfamily 2 members of SNF1-related kinases (SnRK2 kinases) by dephosphorylating serine and threonine residues in their activation loop [4] [5] [6] [7] . ABA-induced PP2C inhibition leads to SnRK2 activation by autophosphorylation and/or phosphorylation by upstream kinases. Activated SnRK2s in turn phosphorylate and activate downstream effectors such as the basic leucine-zipper transcription factors called ABFs/AREBs to switch on stress-response programs [7] [8] [9] [10] [11] [12] [13] [14] [15] . The molecular mechanisms of ABA binding to the PYR/PYL receptors and PP2C inhibition have been revealed by a series of recent structural studies [16] [17] [18] [19] [20] . These structural studies highlight a conserved gate-latch-lock mechanism underlying ABA perception and signal transduction [16] [17] [18] [19] [20] . The apo ABA receptor contains an open ligand-binding pocket. ABA binding induces the closure of the ligand entry gate, which allows the receptor to bind and competitively inhibit PP2Cs. The interactions between PP2Cs and ABA receptors further induce conformational changes that lock the receptor in the closed conformation.
a r t i c l e s
The plant hormone abscisic acid (ABA) controls many important physiological processes, including seed germination, bud dormancy and adaptive responses to environmental stresses such as drought and salinity. Whereas downstream mediators of ABA signaling have been established, the protein receptors for ABA have eluded identification for many years because of the high level of receptor redundancy. Through chemical genetics and yeast two-hybrid screening, a new class of START proteins has recently been described as ABA receptors in Arabidopsis thaliana [1] [2] [3] . These receptors are designated as pyrabactin resistance 1 (PYR1) and 13 members of PYR1-like (PYL) receptors 1 or as regulatory components of ABA receptors (RCAR) 2 . ABA binding to these receptors increases their ability to bind and inhibit type 2C protein phosphatases (PP2Cs), such as ABI1, ABI2 and HAB1. In the absence of ABA, these PP2Cs bind and inactivate subfamily 2 members of SNF1-related kinases (SnRK2 kinases) by dephosphorylating serine and threonine residues in their activation loop [4] [5] [6] [7] . ABA-induced PP2C inhibition leads to SnRK2 activation by autophosphorylation and/or phosphorylation by upstream kinases. Activated SnRK2s in turn phosphorylate and activate downstream effectors such as the basic leucine-zipper transcription factors called ABFs/AREBs to switch on stress-response programs [7] [8] [9] [10] [11] [12] [13] [14] [15] . The molecular mechanisms of ABA binding to the PYR/PYL receptors and PP2C inhibition have been revealed by a series of recent structural studies [16] [17] [18] [19] [20] . These structural studies highlight a conserved gate-latch-lock mechanism underlying ABA perception and signal transduction [16] [17] [18] [19] [20] . The apo ABA receptor contains an open ligand-binding pocket. ABA binding induces the closure of the ligand entry gate, which allows the receptor to bind and competitively inhibit PP2Cs. The interactions between PP2Cs and ABA receptors further induce conformational changes that lock the receptor in the closed conformation.
Although the basic mechanisms of receptor activation from ABA binding to PP2C inhibition are illustrated by structures, fundamental questions pertaining to the functional regulation of the receptor activity remain. For example, the endogenous concentration of ABA in unstressed conditions is estimated to be 0.7-1.5 fg per guard-cell pair, which corresponds to 0.7-1.5 μM [21] [22] [23] , a concentration range that is sufficient to bind and activate several different recombinant PYL-PP2C complexes [1] [2] [3] 16 . ABA concentrations were also determined in vivo in guard cells by using ABA-responsive reporter gene activation, indicating a cellular ABA level in unstressed conditions above a threshold of 0.3 μM 24 . Furthermore, several subtypes of ABA receptors (PYL5-PYL13) show ABA-independent interactions with PP2Cs 1,2 , yet the ABA response is inactivated in unstressed plants. These observations suggest that some or all ABA receptors need to be inhibited in unstressed conditions, but the mechanism of how ABA receptors are inhibited is unknown.
Whereas ABA is a pan-agonist of ABA receptors, pyrabactin was identified as selective agonist of PYR1 in a seed-germination assay 25 that promoted the interaction of the HAB1 PP2C with a subset of PYR/PYL proteins 1 . Here we show that pyrabactin is, unexpectedly, a PYL2-selective antagonist, and we identify the mechanism of receptorselective activation and inhibition by pyrabactin. Our results illustrate a new concept of ABA receptor antagonism, lay a theoretic foundation for future identification of physiological ABA receptor antagonists and establish a structural framework to screen and design subtype-selective agonists and antagonists for unraveling ABA biology.
RESULTS

Subtype-selective activation and inhibition of ABA receptors
Pyrabactin selectively promoted the interaction of the HAB1 PP2C with PYR1, PYL1 and PYL3, but not PYL2 and PYL4, in yeast twohybrid assays 1 . To determine the biochemical basis of these observations, we used purified proteins of PYR1 and PYL1-PYL6 ( Fig. 1a and Supplementary Fig. 1a ) to measure their interactions with the three PP2Cs, HAB1, ABI1 and ABI2, in vitro. Pyrabactin promoted PYR1 to interact with all three PP2Cs, consistent with its original identification as a selective PYR1 agonist. Pyrabactin also promoted the interaction of PYL1, PYL3, PYL6 and, unexpectedly, PYL4 with the three PP2Cs. In contrast, pyrabactin did not promote PYL2 interaction with any of the three PP2Cs. In phosphatase assays, pyrabactin promoted PYR1, PYL1, PYL3, PYL5 and PYL6, but not PYL2 and PYL4, to inhibit all three PP2Cs (Fig. 1b and Supplementary Fig. 1b) . Notably, in contrast to other receptors analyzed, PYL6 has high basal activity in both PP2C binding and inhibition. These results show different modes of PP2C binding and PP2C inhibition for different members of the PYR/PYL family.
Unexpectedly, pyrabactin not only failed to activate PYL2 but also inhibited ABA-dependent PYL2 interaction with all three PP2Cs in a concentration-dependent manner, suggesting that pyrabactin may be a PYL2-selective antagonist (Fig. 1c) . Consistent with this observation, pyrabactin did not promote PYL2 to inhibit the three PP2Cs (Fig. 1b) , but high concentrations of pyrabactin reversed ABA-dependent inhibition of PP2Cs by PYL2 (Fig. 1d) . In addition, pyrabactin promoted PYR1 in a concentration-dependent manner to induce the expression of RD29B-LUC, an ABA-inducible reporter ( Supplementary Fig. 1c ), but inhibited PYL2 and ABA-dependent induction in a reconstituted ABA signaling pathway in Arabidopsis protoplasts 26 (Fig. 1e) . These results collectively establish that pyrabactin is a PYL2-selective antagonist.
Structure of the PYL1-pyrabactin-ABI1 agonist complex
To understand the molecular basis of pyrabactin as a subtype-selective agonist and antagonist of ABA receptors, we determined the crystal structures of a PYL1-pyrabactin-ABI1 ternary complex and a PYL2-pyrabactin binary complex at resolutions of 2.15 Å and 1.85 Å, respectively. We solved these structures by molecular replacement starting from the PYL1-ABA-ABI1 and apo PYL2 structures 16, 17, 20 , with the statistics of data and structures summarized in Table 1 . For the PYL1-ABA-ABI1 complex, there are two ternary complexes in the P1 unit cell. Consistent with the agonist property of pyrabactin for PYL1, the overall arrangement of the PYL1-pyrabactin-ABI1 complex resembles the agonist structure of the PYL1-ABA-ABI1 complex, with the gate and latch loops of PYL1 (residues 112-116 and 142-144) adopting the closed conformation that is further stabilized by the insertion of the locking residue, Trp300 from ABI1 (see Fig. 2a-c and Supplementary Fig. 2a for an overlay of the ABA-bound and pyrabactin-bound structures). In the complex, the gate-latch interface is tightly packed against the active site of ABI1, therefore providing a mechanism of phosphatase inhibition.
Pyrabactin, which is clearly defined by a high-resolution electron density map, adopts a π-shape configuration in the PYL1 pocket ( Fig. 2d and Supplementary Fig. 2b ). The intermolecular interactions between pyrabactin and PYL1 are diagrammed in Figure 2e . The binding mode of pyrabactin mimics that of ABA, with the naphthalene double ring of pyrabactin overlapping extensively with the cyclohexene ring of ABA (Fig. 2f) . The bromide group from the naphthalene ring forms several van der Waals interactions with Leu-Pro-Ala, three residues from the ligand entry gate (Fig. 2d,e) , and these interactions are important to keep the gate in the closed conformation, as the equivalent P88S mutation in PYR1 abolishes its responses to pyrabactin 1 . The nitrogen from the pyridine ring of pyrabactin functionally mimics the acidic group of ABA and forms a water-mediated hydrogen bond with Lys86. These interactions between pyrabactin and PYL1 provide a basis for understanding the structure-function relationship of pyrabactin derivatives and help to explain why the nitrogen group of pyridine is required for agonist activity of pyrabactin 1 .
Structure of the PYL2-pyrabactin antagonist complex
We obtained the PYL2-pyrabactin crystals under the same conditions as those for the ABA-bound PYL2, but the crystals were formed in the same space group as the apo PYL2. In contrast to the closed conformation of PYL1, pyrabactin-bound PYL2 adopts an open conformation where its ligand entry gate assumes a r t i c l e s a position similar to that in the apo PYL2 structure (Fig. 3) . There are three PYL2-pyrabactin complexes in each asymmetric unit, and pyrabactin assumes a similar π configuration in each complex. Notably, the binding orientation of pyrabactin in PYL2 is flipped 180° from that of PYL1. In this conformation, pyrabactin forms extensive interactions with PYL2 ( Fig. 3c,d ). The sulfonamide functional group mimics the acidic group of ABA, forming two water-mediated hydrogen bonds with Lys64 (Lys89 equivalent in PYL1) and one water-mediated hydrogen bond with Glu98. The naphthalene ring of pyrabactin forms parallel packing interactions with the phenol ring of Tyr124 and the pyridine ring of pyrabactin (Fig. 3c) . We also determined the crystal structure of pyrabactin itself, which adopts a more extended conformation than that in the ligand binding pockets of PYL1 and PYL2 ( Supplementary  Fig. 2c ), indicating that pyrabactin undergoes an induced fit to accommodate the shape of the ligand binding pockets. Fig. 3 ). Structural modeling indicated that Val166/Ala190 and Val170/Ile194 changes would not interfere with the binding of pyrabactin in either the PYL1 or the PYL2 conformation. In contrast, the Val114/Ile137 change in PYL1 collides with the naphthalene ring of pyrabactin in the PYL2 conformation (C-C distance of 2.2 Å) (Fig. 4a) and forces pyrabactin to flip by 180°. Mutation of PYL1 Ile137 to valine, which was predicted to allow pyrabactin to adopt the PYL2-bound conformation, converted PYL1 to a pyrabactin-inhibited receptor. Due to the very weak pyrabactin agonist activity in wild-type PYL1, this change is most clearly seen in the context of two mutant PYL1 receptors, in which we exchanged residues Ala190 and Val193 from helix 3 against larger side chains that stabilize the binding of pyrabactin, as modeled in Figure 4b ,c. A190V and V193I mutations increased PYL1 agonist activity ( Fig. 4d and Supplementary  Fig. 4) . Introduction of the I137V mutation into either PYL1 A190V or PYL1 V193I shifted the equilibrium from a predominantly pyrabactin-activated receptor to a predominantly pyrabactin-antagonized receptor, for which pyrabactin inhibited ABA-promoted activation in a concentration-dependent manner (Fig. 4e-h) . From these results, we conclude that the removal of a single methyl group (isoleucine versus valine) is sufficient to convert PYL1 from a pyrabactin-activated receptor into a pyrabactin-repressed receptor. 
A93F converts PYL2 to a pyrabactin-activated receptor
Another key question is why pyrabactin binding does not activate PYL2. Structural analysis indicates that pyrabactin in the context of PYL2 does not form any direct interactions with residues from the ligand entry gate. The closest distance between the pyridine ring of pyrabactin and the Leu-Pro-Ala gating residues is 4.8-7.0 Å when the Leu-Pro-Ala loop assumes the ABA-bound closed conformation, but the closest distance is 11-13 Å when the Leu-Pro-Ala gate is in open conformation, as seen in the pyrabactin-bound PYL2 structure (Fig. 3a) . In contrast, the distance of the naphthalene double ring of pyrabactin or the cyclohexene ring of ABA to the three side chains of the Leu-Pro-Ala gate in the PYL1 structure is 3.4-4.6 Å (Fig. 2b) , a range for strong van der Waals interactions, thus helping to keep the Leu-Pro-Ala gate in the closed conformation. These observations suggest that the antagonism of pyrabactin to PYL2 is because the pyridine group is positioned too far away to make any direct contacts with the Leu-Pro-Ala loop that would help keep the gate closed. To validate this hypothesis, we changed the alanine in the Leu-Pro-Ala loop to a larger residue. Indeed, mutation of A93F, designed to close the distance between the gate loop and the pyridine ring, converted PYL2 from a pyrabactin-repressed to a pyrabactin-activated receptor, as determined by PP2C binding and phosphatase assays (Fig. 5a,b) . As expected from structural modeling, replacement of the gate residue Ala93 with the bulky phenylalanine ring also abrogated ABA to promote PYL2 activation (Fig. 5a,b) .
Crystal structures of PYL2 A93F-pyrabactin agonist complexes
To gain further understanding on how the A93F mutation converts PYL2 into a pyrabactin-activated, ABA-insensitive receptor, we solved the crystal structures of a dimeric complex of PYL2 A93F bound to pyrabactin at a resolutions of 2.10 Å and two trimeric complexes of PYL2 A93F-pyrabactin bound to ABI2 and HAB1 at a resolution of 2.10 Å and 2.55 Å, respectively. The two trimeric structures closely resemble the active PYL2-ABA-HAB1 (ref. 16 ) and PYL1-ABA-ABI1 (refs. 17,20) structures, with the gate and latch loops in the closed conformation and the PP2C locking residue (Trp290 in ABI2 and Trp385 in HAB1) inserted between the gate and latch to make water-mediated contacts with the bound pyrabactin ( Fig. 5c and Supplementary Fig. 5a,b) . Pyrabactin adopts an intermediate conformation between the agonist and antagonist conformation (Fig. 5c ) to allow formation of van der Waals interactions with Phe93, which contacts both ring systems of pyrabactin (Fig. 5d) , thereby stabilizing the gate in the closed conformation as predicted. The dimeric PYL2 A93F-pyrabactin structure shows mixed conformations of the activated and repressed receptors for the ligand entry gate and latch loops ( Fig. 5e and Supplementary Fig. 5c ). Although the gate adopts an open conformation with Phe93 facing away from the ligand binding pocket as Ala93 in wild-type apo PYL2 (Fig. 5e) , the latch is deposited into the active conformation. The latch residue His119 is flipped into the ligand binding pocket, mimicking its conformation in the active trimeric complex (Fig. 5c,e) , and forms direct contacts with pyrabactin (Fig. 5f) . Glu118, the residue immediately preceding the His-Arg-Leu latch, is flipped outside of the pocket, as in ABA-activated PYL2 (ref. 16) , to allow closure of the gate onto the latch upon PP2C binding (Fig. 5e) . In this state, the mutated receptor is poised to be activated upon the binding of pyrabactin and a PP2C, therefore providing the basis of pyrabactin agonism by the mutated receptor.
Identification of pyrabactin-based ABA receptor agonists
The ability to switch the activation and repression responses of PYL1 and PYL2 to pyrabactin by single point mutations shows the detailed levels of our mechanistic understanding of ABA receptor activation and repression, and provides a rational model to screen for novel ABA receptor activators and inhibitors. To demonstrate the validity of this approach, we explored the structural information of pyrabactin bound to PYL1 and PYL2. In both the PYL1 and PYL2 structures, the sulfonamide group of pyrabactin forms extensive interactions with the receptor by mimicking the carboxylate group of ABA. We therefore searched virtual library servers (Chembridge (http://www.hit2lead. com) and ZINC8 (http://zinc.docking.org)) representing more than 10 million commercially available compounds for molecules containing a naphthalene-1-sulfonamide group. We then computationally docked these compounds into the PYL1 ligand binding pocket (Supplementary Fig. 6 ). To validate our docking approach, we tested the top 64 docking matches for their ability to promote PYR1-PP2C interaction and PYR1-dependent inhibition of PP2C activity in vitro. At least four of the 64 compounds efficiently activated PYR1 with a r t i c l e s efficacies (Fig. 6a,b and Supplementary Fig. 7 ) and EC 50 values ( Fig. 6c and Supplementary  Fig. 8 ) similar to that of pyrabactin. The success of this virtual docking exercise shows the proof of concept for future screening and design of potent ABA receptor ligands to explore ABA biology and for agriculture applications.
DISCUSSION
In this study, we show that pyrabactin has both receptor-selective agonist and antagonist properties by receptor-PP2C interaction assays, PP2C inhibition assays and protoplast reporter assays. Crystal structures of the PYL2-pyrabactin antagonist and the PYL1-pyrabactin-ABI1 agonist complexes reveal that pyrabactin adopts two different pseudosymmetrical configurations. In the PYL1 structure, pyrabactin mimics ABA. The bromo-naphtalene group of pyrabactin interacts with the same three gate residues (Leu114-Pro115-Ala116) as the ABA cyclohexene ring to pull the gate into the closed position, therefore allowing the formation of the gate-latch interface that docks into the active site of ABI1. In the antagonist conformation, pyrabactin occupies the ABA-binding pocket but does not interact with the gate residues, lacking the interacting energy to pull the gate into the closed position and therefore leaving the gate in the inactive open conformation. These results further highlight opening and closing of the ligand entry gate as the critical mechanism that determines activation and inhibition of ABA receptors. The conceptually most exciting aspect of these studies is the identification of ABA receptor antagonism. Our works provide comprehensive evidence for the phenomenon of ABA receptor antagonism and its underlying mechanisms through combinatorial approaches of structural, biochemical, mutagenesis and chemical screening studies. The antagonism concept of ABA receptors mirrors the mechanism of the receptor activation and has profound implications in the regulation of ABA receptor physiology. It is well documented that the concentration of endogenous ABA in unstressed plant tissues is in a range that is sufficient to bind and activate several different recombinant PYL-PP2C complexes [1] [2] [3] 16, 21, 24, 27, 28 . In addition, some ABA receptors, including PYL6, have high levels of constitutive activity in inhibition of all three PP2Cs (Fig. 1b and Supplementary Fig. 1b ) and are coexpressed with these PP2Cs in several organs, including seeds and guard cells (Supplementary Fig. 9 ), yet the ABA response is silent in normal unstressed plants. This raises the important question of how the basal activity of ABA receptors is inhibited. Our data lead to the intriguing hypothesis of the existence of physiological antagonists that can inhibit the basal activation of ABA receptors. We speculate that likely candidates are catabolic derivatives or storage forms of ABA, as ABA metabolic products are known to be involved in ABA responses 28 . On the other hand, PYR/PYL receptors are prone to the binding of diverse ligands due to their large hydrophobic pockets, a characteristic shared with other START proteins, which can bind chemically distinct sets of lipids, hormones and antibiotics 29 . As shown in this study, PYR/PYL receptors can bind to pyrabactin and many other sulfonamide derivatives with chemical structures completely different from ABA. Thus, derivatives from other hormone pathways that functionally antagonize ABA pathways could also serve as potential ABA receptor antagonists. The identification of endogenous ABA receptor antagonists will be an exciting direction for future research.
The mechanisms of ABA receptor antagonism presented here also complement the activation mechanism of ABA receptors elucidated by earlier structural studies [16] [17] [18] [19] [20] and provide a full picture for up-and downregulation of ABA receptors. This detailed mechanistic understanding of the receptor regulation has allowed us to manipulate the receptor activation and repression properties as well as ligand specificity, which will be important new tools for metabolic engineering as well as to unravel the biology of individual receptors in the context of high receptor redundancy. Furthermore, the structural information of the ABA receptor agonism and antagonism provides a solid framework for computational screening of virtual chemical libraries, which have allowed us to identify four novel ABA receptor activators. ABA signaling is central in plant resistance to environmental stresses such as drought conditions. The ability of identifying agonists of ABA receptors opens a new avenue for making other small molecules of ABA mimics, which should have practical applications for improving crop yield under stress conditions.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
